OTC Markets
11:39:19 23/05/2024 pm IST
5-day change
1st Jan Change
0.093
USD
+74.48%
+3.33%
-7.09%
James Sapirstein Resigns as Interim Chief Executive Officer of Marizyme, Inc
June 28, 2021 at 05:48 pm IST
On June 24, 2021, James Sapirstein resigned as Interim Chief Executive Officer of Marizyme, Inc.
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
14/05
CI
Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors
06/02
CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
15/11
CI
Marizyme, Inc. Announces FDA Clearance for Product, Duragraft
06/23/06
CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
19/23/19
CI
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
16/23/16
CI
Marizyme, Inc. announced a financing transaction
15/23/15
CI
Marizyme, Inc. Announces IP Developments for DuraGraft and its Pipeline of Products
10/23/10
CI
Marizyme, Inc. announced that it has received $0.265216 million in funding
10/23/10
CI
Marizyme, Inc. announced that it expects to receive $0.265216 million in funding
18/23/18
CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
25/23/25
CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
25/23/25
CI
Marizyme, Inc. Auditor Raises 'Going Concern' Doubt
24/23/24
CI
Marizyme, Inc. announced that it expects to receive $1 million in funding from Walleye Capital LLC
07/23/07
CI
Marizyme, Inc. announced that it has received $0.75 million in funding
28/22/28
CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
14/22/14
CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
16/22/16
CI
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
16/22/16
CI
Marizyme, Inc. Appoints Michael R. Stewart to the Board, Effective June 1, 2022
12/22/12
CI
Marizyme, Inc. Appoints Nilesh Patel to Board as Director
25/22/25
CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
01/22/01
CI
Marizyme, Inc. Auditor Raises 'Going Concern' Doubt
31/22/31
CI
MMarizyme, Inc. Announces Allowance of Patent Application for Duragraft® by United States Patent and Trademark Office
06/22/06
CI
Marizyme, Inc. Appoints David Barthel as Member of Board of Directors
24/21/24
CI
Marizyme, Inc. Appoints George Kovalyov as CFO
24/21/24
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
More about the company
1st Jan change
Capi.
-7.09% 12.26M +9.86% 118B +10.11% 106B -11.46% 23.4B -1.69% 22.1B -10.23% 18.34B -41.92% 16.59B -15.61% 15.97B +6.47% 14.03B +16.70% 11.67B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
MARIZYME, INC. 
